[Ivosidenib (acute myeloid leukaemia, IDH1 R132 mutation, first line, combination with azacitidine) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018005240
German
Original Title:
Ivosidenib (akute myeloische Leukämie)
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/g23-16.html
Year Published:
2023
URL for published report:
https://www.iqwig.de/download/g23-16_ivosidenib_bewertung-35a-absatz-1-satz-11-sgb-v_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
DOI:
10.60584/G23-16
MeSH Terms
- Leukemia, Myeloid, Acute
- Antineoplastic Agents
- Enzyme Inhibitors
Keywords
- Ivosidenib
- Leukemia – Myeloid – Acute
- Health Care Costs
- Epidemiology
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.